Loading analysis...
Loading Truth Social...
Loading live updates...
—
S&P 500— —
Nasdaq— —
Dow Jones— —
载入时间机器…
SLS 最新新闻
SLS 的最新新闻报道,汇总自华尔街日报、彭博、纽约时报、金融时报与 Google 新闻,实时更新,免费无广告。标题保留原文。
- SELLAS Life Sciences: Valued For Perfection, REGAL Trial Success Probability Priced In
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
- SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data
- SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer
- Why Analysts Think Sellas Life Sciences Stock Can Gain 150% From Here
- SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED)
- Sellas CEO Stergiou Says ‘Rigorous, Unblinded’ Data From Pivotal AML Trial Will 'Speak For Itself' As REGAL Catalyst Nears
- Why Are Nasdaq, S&P 500 Futures Subdued Premarket? NVDA, AAPL, INTC, CRWD, RKLB, SLS Stocks In Focus
- Why Are Nasdaq, S&P 500 Futures Subdued Premarket? NVDA, AAPL, INTC, CRWD, RKLB, SLS Stocks In Focus
- Sellas Life (SLS) Falls 13% as Firm Still Mum on ALM Drug Candidate
- When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
- Why Are Nasdaq, S&P 500 Futures Slipping Premarket? NVDA, INTU, CRWD, CRM, CRML, SLS Stocks In Focus
- Sellas Traders See Pancreatic Cancer Race After RVMD’s Drug Approval — But Near-Term Focus Remains On SLS’s Leukemia Pipeline
- SLS Stock Charges Ahead As AML Trial Buzz Builds: Report Claims Regal Hit 80th Event — Retail Isn’t Convinced
- SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation
Settings
Appearance
Card Style
Language
Notifications
Live View Style
Trump Truth Social
About
Version
2.6.1
Data Source
r/wallstreetbets
AI Engine
ChatGPT/Gemini/Claude
MCP Server
https://mcp.sellthenews.org/mcp
Contact Us
[email protected]